BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

CytoDyn 

5 Centerpointe Drive
Suite 400
Lake Oswego  Oregon  97035  U.S.A.
Phone: 971-204-0382 Fax: n/a


SEARCH JOBS




Industry
Biotechnology






 Company News
CytoDyn Information Now Available Through S&P Capital IQ Corporation Records Program 11/25/2014 9:36:38 AM
CytoDyn Announces 100% Success With PRO 140 In Four-Week Monotherapy Clinical Trial 10/13/2014 8:06:38 AM
CytoDyn Announces Investment Community Call To Discuss Results From Its Treatment Substitution Clinical Trial In Patients With HIV 10/13/2014 7:42:21 AM
CytoDyn Appoints Carl Dockery To Board Of Directors 10/2/2014 7:47:26 AM
CytoDyn Announces Webcast For Annual Shareholder Meeting 8/18/2014 7:01:27 AM
CytoDyn Announces Investment Community Call To Discuss Interim Results From Its Treatment Substitution Study In Patients With HIV 7/31/2014 8:59:56 AM
CytoDyn Announces Positive Interim Results From Its Treatment Substitution Study in Patients With HIV 7/31/2014 6:56:44 AM
CytoDyn Announces Investor Call To Provide Update On Clinical Development Strategy 5/15/2014 11:38:21 AM
CytoDyn Announces First HIV Patient Dosing With PRO 140 In Phase 2b Clinical Trial For Treatment Substitution Protocol 5/14/2014 11:45:54 AM
CytoDyn Announces Investor Call To Provide Update On Clinical Development Strategy 3/19/2014 9:06:58 AM
12345678910...